Valion Bio (VBIO) Retained Earnings (2021 - 2026)
Valion Bio (VBIO) posted quarterly Retained Earnings of -$52.6 million for Q4 2025, down 20.8% year-over-year from -$66.4 million in Q4 2024, and down 199.19% quarter-over-quarter from $53.0 million in Q3 2025.
Valion Bio (VBIO) Retained Earnings (2021 - 2026) Analysis & Trends
Valion Bio's Retained Earnings history runs 5 years deep, the most recent figure standing at -$52.6 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 20.8% year-over-year to -$52.6 million; the TTM figure through Dec 2025 stood at -$52.6 million (down 20.8% YoY), while the FY2025 annual figure was -$52.6 million, down 20.8% from the prior year.
- Retained Earnings for Q4 2025 stood at -$52.6 million, down from $53.0 million in the prior quarter.
- The five-year high for Retained Earnings was $53.0 million in Q3 2025, with the low at -$52.6 million in Q4 2025.
- The 5-year median for Retained Earnings is -$24.8 million (2022), against an average of -$2.8 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings plunged 207.49% in 2023, then soared 230.74% in 2024.
- Valion Bio's Retained Earnings stood at $32.8 million in 2021, then plunged by 190.33% to -$29.6 million in 2022, then fell by 27.81% to -$37.9 million in 2023, then decreased by 14.93% to -$43.5 million in 2024, then decreased by 20.8% to -$52.6 million in 2025.
- Business Quant data shows VBIO's Retained Earnings at -$52.6 million in Q4 2025, $53.0 million in Q3 2025, and $50.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | 70.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.75 Mn |
| Dec 31, 2025 | -52.60 Mn |
| Sep 30, 2025 | 53.03 Mn |
| Jun 30, 2025 | 50.29 Mn |
| Mar 31, 2025 | 48.08 Mn |
| Dec 31, 2024 | -43.54 Mn |
| Sep 30, 2024 | 44.90 Mn |
| Jun 30, 2024 | -40.60 Mn |
| Mar 31, 2024 | 41.52 Mn |
| Dec 31, 2023 | -37.89 Mn |
| Sep 30, 2023 | -35.64 Mn |
| Jun 30, 2023 | -33.90 Mn |
| Mar 31, 2023 | -31.76 Mn |
| Dec 31, 2022 | -29.64 Mn |
| Sep 30, 2022 | 33.16 Mn |
| Jun 30, 2022 | -24.80 Mn |
| Mar 31, 2022 | -21.80 Mn |
| Dec 31, 2021 | 32.82 Mn |